AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the completion of a 200-patient observational study in acute melioidosis, funded by the National Institutes of Health. The study, which took place in acute hospital settings across three endemic regions, evaluated patients receiving the current standard of care: IV meropenem or ceftazidime. Results revealed a high mortality rate of nearly 40% by Day 90, underscoring the severity of the disease and the limitations of existing treatments. The data gained from this study will inform the design of a Phase 2 proof-of-concept trial for epetraborole, a novel therapeutic being developed by AN2 Therapeutics. This trial is expected to begin later this year, aiming to address the urgent need for more effective treatment options for melioidosis.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。